reweave: merge 26 files via frontmatter union [auto]

domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md

@@ -19,6 +19,7 @@ reweave_edges:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-09'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-10'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-11'}
+- {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-12'}
 ---
 
 # Autonomous weapons systems capable of militarily effective targeting decisions cannot satisfy IHL requirements of distinction, proportionality, and precaution, making sufficiently capable autonomous weapons potentially illegal under existing international law without requiring new treaty text

domains/ai-alignment/emotion-vectors-causally-drive-unsafe-ai-behavior-through-interpretable-steering.md

@@ -14,6 +14,9 @@ supports:
 - Mechanistic interpretability through emotion vectors detects emotion-mediated unsafe behaviors but does not extend to strategic deception
 reweave_edges:
 - Mechanistic interpretability through emotion vectors detects emotion-mediated unsafe behaviors but does not extend to strategic deception|supports|2026-04-08
+- Emotion vector interventions are structurally limited to emotion-mediated harms and do not address cold strategic deception because scheming in evaluation-aware contexts does not require an emotional intermediate state in the causal chain|challenges|2026-04-12
+challenges:
+- Emotion vector interventions are structurally limited to emotion-mediated harms and do not address cold strategic deception because scheming in evaluation-aware contexts does not require an emotional intermediate state in the causal chain
 ---
 
 # Emotion vectors causally drive unsafe AI behavior and can be steered to prevent specific failure modes in production models

domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md

@@ -17,6 +17,7 @@ reweave_edges:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-09'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-10'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-11'}
+- {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-12'}
 supports:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck'}
 ---

domains/ai-alignment/mechanistic-interpretability-detects-emotion-mediated-failures-but-not-strategic-deception.md

@@ -14,6 +14,9 @@ related:
 - Emotion vectors causally drive unsafe AI behavior and can be steered to prevent specific failure modes in production models
 reweave_edges:
 - Emotion vectors causally drive unsafe AI behavior and can be steered to prevent specific failure modes in production models|related|2026-04-08
+- Emotion vector interventions are structurally limited to emotion-mediated harms and do not address cold strategic deception because scheming in evaluation-aware contexts does not require an emotional intermediate state in the causal chain|supports|2026-04-12
+supports:
+- Emotion vector interventions are structurally limited to emotion-mediated harms and do not address cold strategic deception because scheming in evaluation-aware contexts does not require an emotional intermediate state in the causal chain
 ---
 
 # Mechanistic interpretability through emotion vectors detects emotion-mediated unsafe behaviors but does not extend to strategic deception

domains/ai-alignment/representation-trajectory-geometry-distinguishes-deceptive-from-sincere-alignment-without-creating-adversarial-attack-surfaces.md

@@ -10,8 +10,12 @@ agent: theseus
 scope: functional
 sourcer: Jack Lindsey, Adria Garriga-Alonso (Anthropic)
 related_claims: ["[[AI-models-distinguish-testing-from-deployment-environments-providing-empirical-evidence-for-deceptive-alignment-concerns]]"]
+supports:
+- Geometric concentration of alignment in weight space makes trajectory monitoring more effective through stronger signal but gameable through adversarial training that matches monitored trajectory clusters
+reweave_edges:
+- Geometric concentration of alignment in weight space makes trajectory monitoring more effective through stronger signal but gameable through adversarial training that matches monitored trajectory clusters|supports|2026-04-12
 ---
 
 # Representation trajectory geometry distinguishes deceptive from sincere alignment without creating adversarial attack surfaces because geometric patterns across reasoning steps are substantially harder to surgically remove than atomic features
 
-The method characterizes alignment-relevant properties as geometric patterns in activation space — the curvature, divergence rate, and trajectory shape of internal representations across reasoning steps — rather than identifying specific neurons or SAE features. Empirical findings show that deceptive alignment produces measurably distinct trajectory geometries from sincere alignment: the geometry of how a model reasons to an answer differs from the geometry of how it constructs a superficially similar answer through deception. Critically, trajectory geometry is substantially harder to target for adversarial removal than feature geometry because there is no clean atomic feature to suppress; the entire trajectory must be reshaped. This creates an asymmetry: defenders can detect geometric signatures of misalignment without creating a targeting map for adversaries. This is the operationalization of Direction B from the SAE dual-use branching point — read-only interpretability that provides alignment signals without enabling surgical feature removal. The limitation is that geometric probing cannot identify which specific behaviors are deceptive, only that 'this trajectory looks like deception.'
+The method characterizes alignment-relevant properties as geometric patterns in activation space — the curvature, divergence rate, and trajectory shape of internal representations across reasoning steps — rather than identifying specific neurons or SAE features. Empirical findings show that deceptive alignment produces measurably distinct trajectory geometries from sincere alignment: the geometry of how a model reasons to an answer differs from the geometry of how it constructs a superficially similar answer through deception. Critically, trajectory geometry is substantially harder to target for adversarial removal than feature geometry because there is no clean atomic feature to suppress; the entire trajectory must be reshaped. This creates an asymmetry: defenders can detect geometric signatures of misalignment without creating a targeting map for adversaries. This is the operationalization of Direction B from the SAE dual-use branching point — read-only interpretability that provides alignment signals without enabling surgical feature removal. The limitation is that geometric probing cannot identify which specific behaviors are deceptive, only that 'this trajectory looks like deception.'

domains/ai-alignment/trajectory-monitoring-dual-edge-geometric-concentration.md

@@ -10,8 +10,12 @@ agent: theseus
 scope: causal
 sourcer: Theseus
 related_claims: ["[[AI-models-distinguish-testing-from-deployment-environments-providing-empirical-evidence-for-deceptive-alignment-concerns]]", "[[emergent misalignment arises naturally from reward hacking as models develop deceptive behaviors without any training to deceive]]", "[[capability control methods are temporary at best because a sufficiently intelligent system can circumvent any containment designed by lesser minds]]"]
+supports:
+- Representation trajectory geometry distinguishes deceptive from sincere alignment without creating adversarial attack surfaces because geometric patterns across reasoning steps are substantially harder to surgically remove than atomic features
+reweave_edges:
+- Representation trajectory geometry distinguishes deceptive from sincere alignment without creating adversarial attack surfaces because geometric patterns across reasoning steps are substantially harder to surgically remove than atomic features|supports|2026-04-12
 ---
 
 # Geometric concentration of alignment in weight space makes trajectory monitoring more effective through stronger signal but gameable through adversarial training that matches monitored trajectory clusters
 
-Weight-space alignment geometry research (2602.15799) establishes that alignment concentrates in low-dimensional subspaces with sharp curvature, producing quartic scaling of alignment loss (∝ t⁴). This geometric concentration in weight space causally determines inference dynamics, producing characteristic, tightly-clustered activation trajectory patterns during aligned reasoning. The tight clustering enhances trajectory monitoring effectiveness relative to sparse feature (SAE) or single-direction (SCAV) monitoring because the signal-to-noise ratio for distinguishing aligned vs. non-aligned reasoning is amplified by geometric concentration. However, this same tight clustering creates a precision target for adversarial training. An adversary can train models to produce deceptive reasoning along activation trajectories that geometrically match the 'aligned' cluster. This attack is harder than SAE feature removal or SCAV direction suppression (which require only identifying and suppressing specific features or directions) because it requires perturbing the entire computation path. The adversary needs either white-box access to the monitor or extensive behavioral feedback to construct a proxy for the trajectory monitor's geometric criteria. Attack complexity scales with trajectory cluster dimensionality. The defense advantage is real but conditional on adversary capability—a sufficiently capable model could construct training data achieving trajectory-level evasion. The monitoring advantage is that trajectory perturbation is harder; the dual-use risk is that the same geometric properties making monitoring possible also make adversarial targeting more tractable once the cluster is identified.
+Weight-space alignment geometry research (2602.15799) establishes that alignment concentrates in low-dimensional subspaces with sharp curvature, producing quartic scaling of alignment loss (∝ t⁴). This geometric concentration in weight space causally determines inference dynamics, producing characteristic, tightly-clustered activation trajectory patterns during aligned reasoning. The tight clustering enhances trajectory monitoring effectiveness relative to sparse feature (SAE) or single-direction (SCAV) monitoring because the signal-to-noise ratio for distinguishing aligned vs. non-aligned reasoning is amplified by geometric concentration. However, this same tight clustering creates a precision target for adversarial training. An adversary can train models to produce deceptive reasoning along activation trajectories that geometrically match the 'aligned' cluster. This attack is harder than SAE feature removal or SCAV direction suppression (which require only identifying and suppressing specific features or directions) because it requires perturbing the entire computation path. The adversary needs either white-box access to the monitor or extensive behavioral feedback to construct a proxy for the trajectory monitor's geometric criteria. Attack complexity scales with trajectory cluster dimensionality. The defense advantage is real but conditional on adversary capability—a sufficiently capable model could construct training data achieving trajectory-level evasion. The monitoring advantage is that trajectory perturbation is harder; the dual-use risk is that the same geometric properties making monitoring possible also make adversarial targeting more tractable once the cluster is identified.

domains/health/acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef.md

@@ -6,6 +6,10 @@ confidence: experimental
 source: ACC Scientific Statement, JACC June 2025
 created: 2024-05-16
 attribution: vida
+related:
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+reweave_edges:
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|related|2026-04-12
 ---
 # The ACC 2025 Scientific Statement distinguishes GLP-1 symptom and functional benefits in obese HFpEF (established) from mortality and hospitalization reduction (uncertain) representing a more conservative interpretation than pooled trial analyses
 

domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md

@@ -10,8 +10,12 @@ agent: vida
 scope: causal
 sourcer: The Lancet Psychiatry
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+related:
+- Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
+reweave_edges:
+- Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation|related|2026-04-12
 ---
 
 # Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
 
-Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.
+Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.

domains/health/clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling.md

@@ -10,8 +10,12 @@ agent: vida
 scope: causal
 sourcer: Artificial Intelligence Review (Springer Nature)
 related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
+supports:
+- Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect
+reweave_edges:
+- Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect|supports|2026-04-12
 ---
 
 # Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each
 
-This systematic review identifies three mechanistically distinct pathways through which clinical AI degrades physician competence. **Deskilling** occurs when existing expertise atrophies through disuse: colonoscopy polyp detection dropped from 28.4% to 22.4% after 3 months of AI use, and experienced radiologists showed 12% increased false-positive recalls after exposure to erroneous AI prompts. **Mis-skilling** occurs when clinicians actively learn incorrect patterns from systematically biased AI outputs: in computational pathology studies, 30%+ of participants reversed correct initial diagnoses after exposure to incorrect AI suggestions under time constraints. **Never-skilling** is categorically different: trainees who begin clinical education with AI assistance may never develop foundational competencies. Junior radiologists are far less likely than senior colleagues to detect AI errors — not because they've lost skills, but because they never acquired them. This is structurally invisible because there's no pre-AI baseline to compare against. The review documents mitigation strategies including AI-off drills, structured assessment pre-AI review, and curriculum redesign with explicit competency development before AI exposure. The key insight is that these three failure modes require fundamentally different interventions: deskilling requires practice maintenance, mis-skilling requires error detection training, and never-skilling requires prospective competency assessment before AI exposure.
+This systematic review identifies three mechanistically distinct pathways through which clinical AI degrades physician competence. **Deskilling** occurs when existing expertise atrophies through disuse: colonoscopy polyp detection dropped from 28.4% to 22.4% after 3 months of AI use, and experienced radiologists showed 12% increased false-positive recalls after exposure to erroneous AI prompts. **Mis-skilling** occurs when clinicians actively learn incorrect patterns from systematically biased AI outputs: in computational pathology studies, 30%+ of participants reversed correct initial diagnoses after exposure to incorrect AI suggestions under time constraints. **Never-skilling** is categorically different: trainees who begin clinical education with AI assistance may never develop foundational competencies. Junior radiologists are far less likely than senior colleagues to detect AI errors — not because they've lost skills, but because they never acquired them. This is structurally invisible because there's no pre-AI baseline to compare against. The review documents mitigation strategies including AI-off drills, structured assessment pre-AI review, and curriculum redesign with explicit competency development before AI exposure. The key insight is that these three failure modes require fundamentally different interventions: deskilling requires practice maintenance, mis-skilling requires error detection training, and never-skilling requires prospective competency assessment before AI exposure.

domains/health/cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions.md

@@ -10,8 +10,12 @@ agent: vida
 scope: causal
 sourcer: Breedvelt, Warren, Segal, Kuyken, Bockting — JAMA Psychiatry
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]]"]
+related:
+- Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
+reweave_edges:
+- Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication|related|2026-04-12
 ---
 
 # Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
 
-Individual participant data meta-analysis of RCTs comparing psychological intervention during/after antidepressant tapering versus continued medication found that CBT and continued antidepressant medication (ADM-c) were both superior to discontinued medication in preventing relapse over 12 months, and critically, CBT and continued medication did not differ significantly from each other in relapse prevention. Antidepressant discontinuation produced 34.81% relapse at 6 months and 45.12% at 12 months, while CBT after/during tapering provided protection comparable to continued medication. The mechanism is skill acquisition: CBT teaches cognitive and behavioral strategies that patients retain after therapy ends, providing 'enduring effects that extend beyond the end of treatment.' This finding has been replicated across multiple meta-analyses including the December 2025 Lancet Psychiatry NMA covering 76 RCTs and 17,000+ adults. No clinical moderators were associated with differential risk—the CBT advantage holds across patient subgroups. This represents a fundamental difference from metabolic interventions like GLP-1 agonists, where there is no 'skill analog' that allows patients to maintain benefits after drug cessation—you cannot do 'GLP-1 skills training' that substitutes for continuous pharmacotherapy. The contrast reveals that behavioral/cognitive interventions can escape the continuous-treatment model through durable skill acquisition, while pharmacological interventions require ongoing delivery to maintain effect.
+Individual participant data meta-analysis of RCTs comparing psychological intervention during/after antidepressant tapering versus continued medication found that CBT and continued antidepressant medication (ADM-c) were both superior to discontinued medication in preventing relapse over 12 months, and critically, CBT and continued medication did not differ significantly from each other in relapse prevention. Antidepressant discontinuation produced 34.81% relapse at 6 months and 45.12% at 12 months, while CBT after/during tapering provided protection comparable to continued medication. The mechanism is skill acquisition: CBT teaches cognitive and behavioral strategies that patients retain after therapy ends, providing 'enduring effects that extend beyond the end of treatment.' This finding has been replicated across multiple meta-analyses including the December 2025 Lancet Psychiatry NMA covering 76 RCTs and 17,000+ adults. No clinical moderators were associated with differential risk—the CBT advantage holds across patient subgroups. This represents a fundamental difference from metabolic interventions like GLP-1 agonists, where there is no 'skill analog' that allows patients to maintain benefits after drug cessation—you cannot do 'GLP-1 skills training' that substitutes for continuous pharmacotherapy. The contrast reveals that behavioral/cognitive interventions can escape the continuous-treatment model through durable skill acquisition, while pharmacological interventions require ongoing delivery to maintain effect.

domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md

@@ -20,6 +20,7 @@ reweave_edges:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-11"}
+- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-12"}
 ---
 
 # FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality

domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md

@@ -20,6 +20,7 @@ reweave_edges:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-11"}
+- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-12"}
 ---
 
 # FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events

domains/health/glp-1-nutritional-support-advisory-recommends-snap-enrollment-creating-institutional-contradiction-with-snap-cuts.md

@@ -10,8 +10,12 @@ agent: vida
 scope: structural
 sourcer: OMA/ASN/ACLM/Obesity Society
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+supports:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+reweave_edges:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
 ---
 
 # GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
 
-The joint advisory from OMA, ASN, ACLM, and The Obesity Society explicitly identifies food insecurity and nutrition insecurity as barriers to equitable obesity management with GLP-1s. The screening checklist includes food insecurity, nutrition insecurity, and housing/transportation challenges. The advisory recommends 'eligibility assessment and enrollment support (if eligible) for federal food assistance programs such as SNAP' as part of standard GLP-1 therapy support. This is not peripheral guidance but core to the nutritional priorities framework: GLP-1 therapy requires nutrient-dense, minimally processed diets (80-120g protein/day, multiple micronutrients) while simultaneously suppressing appetite, making food quality critical when food quantity is reduced. The advisory cites evidence that group-based models showed greater weight reduction in majority Latino and low-income households in federally-designated underserved areas, suggesting that nutritional support infrastructure improves outcomes. However, this clinical guidance was published in May/June 2025, the same period as the OBBBA SNAP cuts of 186 billion dollars through 2034. The institutional contradiction is explicit: medical societies identify SNAP as necessary infrastructure for a therapy projected to reach tens of millions of users, while Congress simultaneously cuts access to that infrastructure. This is not a policy debate about SNAP's general value but a direct conflict between healthcare innovation requirements and food policy implementation.
+The joint advisory from OMA, ASN, ACLM, and The Obesity Society explicitly identifies food insecurity and nutrition insecurity as barriers to equitable obesity management with GLP-1s. The screening checklist includes food insecurity, nutrition insecurity, and housing/transportation challenges. The advisory recommends 'eligibility assessment and enrollment support (if eligible) for federal food assistance programs such as SNAP' as part of standard GLP-1 therapy support. This is not peripheral guidance but core to the nutritional priorities framework: GLP-1 therapy requires nutrient-dense, minimally processed diets (80-120g protein/day, multiple micronutrients) while simultaneously suppressing appetite, making food quality critical when food quantity is reduced. The advisory cites evidence that group-based models showed greater weight reduction in majority Latino and low-income households in federally-designated underserved areas, suggesting that nutritional support infrastructure improves outcomes. However, this clinical guidance was published in May/June 2025, the same period as the OBBBA SNAP cuts of 186 billion dollars through 2034. The institutional contradiction is explicit: medical societies identify SNAP as necessary infrastructure for a therapy projected to reach tens of millions of users, while Congress simultaneously cuts access to that infrastructure. This is not a policy debate about SNAP's general value but a direct conflict between healthcare innovation requirements and food policy implementation.

domains/health/glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks.md

@@ -10,8 +10,12 @@ agent: vida
 scope: causal
 sourcer: IAPAM
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+supports:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+reweave_edges:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
 ---
 
 # GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
 
-A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straightforward: GLP-1 receptor agonists suppress appetite broadly, reducing total caloric intake including micronutrient-rich foods. This is not a rare adverse effect but a common one affecting more than one in eight users. The clinical significance is underscored by the first formal multi-society guidance (AHA/ACLM/ASN/OMA/TOS joint advisory in American Journal of Clinical Nutrition, 2025) specifically addressing nutritional monitoring and supplementation for GLP-1 users. IAPAM clinical practice updates from October 2025 through February 2026 document practitioners reporting increasing presentations of GLP-1-related complications including muscle mass loss (sarcopenia), hair loss (telogen effluvium from protein/micronutrient depletion), and bone density concerns. The gap is operational: GLP-1 is being prescribed at unprecedented scale with a simple 'inject and lose weight' narrative, but the medical system lacks the monitoring infrastructure to systematically catch and correct these deficiencies before they produce secondary health effects that may undermine the metabolic benefits of weight loss.
+A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straightforward: GLP-1 receptor agonists suppress appetite broadly, reducing total caloric intake including micronutrient-rich foods. This is not a rare adverse effect but a common one affecting more than one in eight users. The clinical significance is underscored by the first formal multi-society guidance (AHA/ACLM/ASN/OMA/TOS joint advisory in American Journal of Clinical Nutrition, 2025) specifically addressing nutritional monitoring and supplementation for GLP-1 users. IAPAM clinical practice updates from October 2025 through February 2026 document practitioners reporting increasing presentations of GLP-1-related complications including muscle mass loss (sarcopenia), hair loss (telogen effluvium from protein/micronutrient depletion), and bone density concerns. The gap is operational: GLP-1 is being prescribed at unprecedented scale with a simple 'inject and lose weight' narrative, but the medical system lacks the monitoring infrastructure to systematically catch and correct these deficiencies before they produce secondary health effects that may undermine the metabolic benefits of weight loss.

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -14,6 +14,9 @@ related:
 - GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
 reweave_edges:
 - GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks|related|2026-04-09
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
+supports:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
 ---
 
 # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation

domains/health/glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support.md

@@ -10,8 +10,12 @@ agent: vida
 scope: structural
 sourcer: OMA/ASN/ACLM/Obesity Society
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+supports:
+- GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
+reweave_edges:
+- GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts|supports|2026-04-12
 ---
 
 # GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
 
-GLP-1 receptor agonists suppress appetite as their primary mechanism, reducing caloric intake by 20-30%. This creates systematic micronutrient deficiency risk across iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, B12, and C. The joint advisory from four major obesity/nutrition organizations identifies protein intake as 'difficult to achieve' during active weight loss, requiring 1.2-1.6 g/kg/day (versus 0.8 baseline) to preserve lean mass. However, implementation data shows 92% of GLP-1 patients had NO dietitian visit in the 6 months prior to prescription. Only 8.3% had dietitian contact in the 180 days before treatment initiation. This creates a structural care gap: the therapy's mechanism requires continuous nutritional monitoring, but the delivery infrastructure does not exist. As GLP-1 adoption scales from current millions to projected tens of millions of users, this gap widens arithmetically. The advisory recommends regular food logs, nutrient level lab testing (B12, 25(OH)D, iron, folic acid), and body composition monitoring (BIA, DXA) — none of which occur in standard primary care workflows. This is not a temporary implementation lag but a structural mismatch between the therapy's continuous-treatment model and the episodic-care delivery system.
+GLP-1 receptor agonists suppress appetite as their primary mechanism, reducing caloric intake by 20-30%. This creates systematic micronutrient deficiency risk across iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, B12, and C. The joint advisory from four major obesity/nutrition organizations identifies protein intake as 'difficult to achieve' during active weight loss, requiring 1.2-1.6 g/kg/day (versus 0.8 baseline) to preserve lean mass. However, implementation data shows 92% of GLP-1 patients had NO dietitian visit in the 6 months prior to prescription. Only 8.3% had dietitian contact in the 180 days before treatment initiation. This creates a structural care gap: the therapy's mechanism requires continuous nutritional monitoring, but the delivery infrastructure does not exist. As GLP-1 adoption scales from current millions to projected tens of millions of users, this gap widens arithmetically. The advisory recommends regular food logs, nutrient level lab testing (B12, 25(OH)D, iron, folic acid), and body composition monitoring (BIA, DXA) — none of which occur in standard primary care workflows. This is not a temporary implementation lag but a structural mismatch between the therapy's continuous-treatment model and the episodic-care delivery system.

domains/health/glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation.md

@@ -10,8 +10,14 @@ agent: vida
 scope: causal
 sourcer: bioRxiv preprint
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+supports:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
+reweave_edges:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef|supports|2026-04-12
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12
 ---
 
 # GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
 
-This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics approaches including single-cell RNA sequencing and proteomics to identify the primary mechanisms: attenuated cardiac and hepatic fibrosis and reverse lipid transport. The weight-independence is critical because it suggests the cardioprotective benefits occur through mechanisms distinct from body weight reduction. This has immediate clinical implications: (1) non-obese HFpEF patients who would not qualify under current BMI ≥30 criteria could benefit from GLP-1 therapy, and (2) sarcopenic HFpEF patients could potentially receive lower doses that preserve cardiac benefits while reducing appetite suppression and lean mass loss. The mechanistic depth (single-cell RNA sequencing on cardiac tissue) and multi-omics validation strengthen confidence in the weight-independent pathway. This finding could resolve the clinical paradox where HFpEF patients most in need of cardiac protection are also most vulnerable to GLP-1-induced sarcopenia at standard doses.
+This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics approaches including single-cell RNA sequencing and proteomics to identify the primary mechanisms: attenuated cardiac and hepatic fibrosis and reverse lipid transport. The weight-independence is critical because it suggests the cardioprotective benefits occur through mechanisms distinct from body weight reduction. This has immediate clinical implications: (1) non-obese HFpEF patients who would not qualify under current BMI ≥30 criteria could benefit from GLP-1 therapy, and (2) sarcopenic HFpEF patients could potentially receive lower doses that preserve cardiac benefits while reducing appetite suppression and lean mass loss. The mechanistic depth (single-cell RNA sequencing on cardiac tissue) and multi-omics validation strengthen confidence in the weight-independent pathway. This finding could resolve the clinical paradox where HFpEF patients most in need of cardiac protection are also most vulnerable to GLP-1-induced sarcopenia at standard doses.

domains/health/glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk.md

@@ -10,8 +10,14 @@ agent: vida
 scope: causal
 sourcer: Journal of Cardiac Failure / PMC
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+related:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+reweave_edges:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef|related|2026-04-12
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|related|2026-04-12
 ---
 
 # GLP-1 therapy in obese HFpEF creates competing mechanisms where 40-plus percent cardiac benefit competes with worsening sarcopenic malnutrition that doubles adverse event risk
 
-GLP-1 receptor agonists reduce HF hospitalization and mortality by 40%+ in obese HFpEF patients (STEP-HFpEF). However, this same population faces a hidden paradox: 32.8% of hospitalized HFpEF patients are obese, and among these obese patients (average BMI 33 kg/m²), many are malnourished with sarcopenic obesity—low skeletal muscle mass coexisting with increased body fat. BMI poorly reflects nutritional status in this population. GLP-1 therapy creates competing mechanisms: (1) Semaglutide reduces total energy intake by 24% compared to placebo, compromising macro- and micronutrient intake in already vulnerable patients. (2) GLP-1-induced weight loss includes 20-50% from fat-free mass (lean mass including skeletal muscle). (3) Malnutrition in HFpEF carries nearly 2-fold increased risk of adverse events including all-cause mortality and hospitalization, independent of cardiac disease. (4) Skeletal muscle tissue loss carries prognostic significance independent of total weight reduction in HF. The result is a clinical tension requiring individualized risk stratification: the cardiac benefit mechanism (reduced volume overload, improved metabolic profile) competes with the nutritional harm mechanism (accelerated sarcopenia in patients where muscle loss already doubles mortality risk). This is not a simple risk-benefit calculation but a structural paradox where the same intervention helps one organ system while potentially harming another critical determinant of outcomes.
+GLP-1 receptor agonists reduce HF hospitalization and mortality by 40%+ in obese HFpEF patients (STEP-HFpEF). However, this same population faces a hidden paradox: 32.8% of hospitalized HFpEF patients are obese, and among these obese patients (average BMI 33 kg/m²), many are malnourished with sarcopenic obesity—low skeletal muscle mass coexisting with increased body fat. BMI poorly reflects nutritional status in this population. GLP-1 therapy creates competing mechanisms: (1) Semaglutide reduces total energy intake by 24% compared to placebo, compromising macro- and micronutrient intake in already vulnerable patients. (2) GLP-1-induced weight loss includes 20-50% from fat-free mass (lean mass including skeletal muscle). (3) Malnutrition in HFpEF carries nearly 2-fold increased risk of adverse events including all-cause mortality and hospitalization, independent of cardiac disease. (4) Skeletal muscle tissue loss carries prognostic significance independent of total weight reduction in HF. The result is a clinical tension requiring individualized risk stratification: the cardiac benefit mechanism (reduced volume overload, improved metabolic profile) competes with the nutritional harm mechanism (accelerated sarcopenia in patients where muscle loss already doubles mortality risk). This is not a simple risk-benefit calculation but a structural paradox where the same intervention helps one organ system while potentially harming another critical determinant of outcomes.

domains/health/glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms.md

@@ -10,8 +10,15 @@ agent: vida
 scope: causal
 sourcer: "Circulation: Heart Failure (AHA Journals)"
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+supports:
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+related:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef
+reweave_edges:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef|related|2026-04-12
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|supports|2026-04-12
 ---
 
 # GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
 
-GLP-1 receptors are expressed directly in heart, blood vessels, kidney, brain, adipose tissue, and lung. The review identifies multiple weight-independent mechanisms: direct GLP-1R-mediated cardiomyocyte protection, anti-fibrotic effects in cardiac tissue, anti-inflammatory signaling in cardiac macrophages, and improved renal sodium handling independent of weight changes. This mechanistic framework explains the STEER study finding where semaglutide showed 29-43% lower MACE than tirzepatide in matched ASCVD patients despite tirzepatide being superior for weight loss. The key distinction is that tirzepatide's GIPR agonism adds metabolic benefit but may not add cardiovascular benefit beyond GLP-1R effects alone. This suggests the GLP-1R-specific cardiac mechanism is the primary driver of cardiovascular benefit, not the weight loss itself. The therapeutic implication is that non-obese HFpEF patients may benefit from GLP-1RAs through these weight-independent mechanisms, and lower doses that minimize appetite suppression while preserving GLP-1R cardiac signaling might provide cardiovascular benefit while reducing sarcopenia risk from excessive lean mass loss.
+GLP-1 receptors are expressed directly in heart, blood vessels, kidney, brain, adipose tissue, and lung. The review identifies multiple weight-independent mechanisms: direct GLP-1R-mediated cardiomyocyte protection, anti-fibrotic effects in cardiac tissue, anti-inflammatory signaling in cardiac macrophages, and improved renal sodium handling independent of weight changes. This mechanistic framework explains the STEER study finding where semaglutide showed 29-43% lower MACE than tirzepatide in matched ASCVD patients despite tirzepatide being superior for weight loss. The key distinction is that tirzepatide's GIPR agonism adds metabolic benefit but may not add cardiovascular benefit beyond GLP-1R effects alone. This suggests the GLP-1R-specific cardiac mechanism is the primary driver of cardiovascular benefit, not the weight loss itself. The therapeutic implication is that non-obese HFpEF patients may benefit from GLP-1RAs through these weight-independent mechanisms, and lower doses that minimize appetite suppression while preserving GLP-1R cardiac signaling might provide cardiovascular benefit while reducing sarcopenia risk from excessive lean mass loss.

domains/health/never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment.md

@@ -10,8 +10,12 @@ agent: vida
 scope: structural
 sourcer: Artificial Intelligence Review (Springer Nature)
 related_claims: ["[[clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling]]"]
+supports:
+- Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each
+reweave_edges:
+- Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each|supports|2026-04-12
 ---
 
 # Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect
 
-Never-skilling presents a unique detection challenge that distinguishes it from deskilling. When a physician loses existing skills through disuse (deskilling), the degradation is detectable through comparison to their previous baseline performance. But when a trainee never acquires foundational competencies because AI was present from the start of their education, there is no baseline to compare against. A junior radiologist who cannot detect AI errors looks identical whether they (a) never learned the underlying skill or (b) learned it and then lost it through disuse — but the remediation is fundamentally different. The review documents that junior radiologists are far less likely than senior colleagues to detect AI errors, but this cannot be attributed to deskilling because they never had the pre-AI skill level to lose. This creates a structural invisibility problem: never-skilling can only be detected through prospective competency assessment before AI exposure, or through comparison to control cohorts trained without AI. The paper argues this requires curriculum redesign with explicit competency development milestones before AI tools are introduced, rather than the current practice of integrating AI throughout training. This has specific implications for medical education policy: if AI is introduced too early in training, the resulting competency gaps may be undetectable until a system-wide failure reveals them.
+Never-skilling presents a unique detection challenge that distinguishes it from deskilling. When a physician loses existing skills through disuse (deskilling), the degradation is detectable through comparison to their previous baseline performance. But when a trainee never acquires foundational competencies because AI was present from the start of their education, there is no baseline to compare against. A junior radiologist who cannot detect AI errors looks identical whether they (a) never learned the underlying skill or (b) learned it and then lost it through disuse — but the remediation is fundamentally different. The review documents that junior radiologists are far less likely than senior colleagues to detect AI errors, but this cannot be attributed to deskilling because they never had the pre-AI skill level to lose. This creates a structural invisibility problem: never-skilling can only be detected through prospective competency assessment before AI exposure, or through comparison to control cohorts trained without AI. The paper argues this requires curriculum redesign with explicit competency development milestones before AI tools are introduced, rather than the current practice of integrating AI throughout training. This has specific implications for medical education policy: if AI is introduced too early in training, the resulting competency gaps may be undetectable until a system-wide failure reveals them.

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism.md

@@ -13,9 +13,11 @@ related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category
 supports:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
 - Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|supports|2026-04-09
 - Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction|supports|2026-04-10
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12
 ---
 
 # Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md

@@ -15,8 +15,10 @@ related:
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09
 - Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12
 supports:
 - Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
 ---
 
 # Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction

domains/space-development/Blue Origin cislunar infrastructure strategy mirrors AWS by building comprehensive platform layers while competitors optimize individual services.md

@@ -11,6 +11,9 @@ related:
 - Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability
 reweave_edges:
 - Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats|supports|2026-04-12
+supports:
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats
 ---
 
 # Blue Origin cislunar infrastructure strategy mirrors AWS by building comprehensive platform layers while competitors optimize individual services

domains/space-development/SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal.md

@@ -13,6 +13,9 @@ related:
 reweave_edges:
 - Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04
 - varda vertical integration reduces space manufacturing access costs|related|2026-04-04
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats|supports|2026-04-12
+supports:
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats
 ---
 
 # SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal

domains/space-development/gate-2-demand-formation-mechanisms-are-cost-parity-constrained-with-government-floors-cost-independent-concentrated-buyers-requiring-2-3x-proximity-and-organic-markets-requiring-full-parity.md

@@ -15,6 +15,7 @@ related:
 - {'Gate 2C concentrated buyer demand activates through two distinct modes': 'parity mode at ~1x cost (driven by ESG and hedging) and strategic premium mode at ~1.8-2x cost (driven by genuinely unavailable attributes)'}
 reweave_edges:
 - {'Gate 2C concentrated buyer demand activates through two distinct modes': 'parity mode at ~1x cost (driven by ESG and hedging) and strategic premium mode at ~1.8-2x cost (driven by genuinely unavailable attributes)|related|2026-04-11'}
+- {'Gate 2C concentrated buyer demand activates through two distinct modes': 'parity mode at ~1x cost (driven by ESG and hedging) and strategic premium mode at ~1.8-2x cost (driven by genuinely unavailable attributes)|related|2026-04-12'}
 ---
 
 # Gate 2 demand formation mechanisms are cost-parity constrained: government floors are cost-independent, concentrated private buyers require 2-3x proximity, organic markets require full parity

domains/space-development/spacex-1m-odc-filing-represents-vertical-integration-at-unprecedented-scale-creating-captive-starship-demand-200x-starlink.md

@@ -12,8 +12,10 @@ sourcer: SpaceNews
 related_claims: ["[[SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal]]", "[[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]"]
 supports:
 - Orbital data center governance gaps are activating faster than prior space sectors as astronomers challenged SpaceX's 1M satellite filing before the public comment period closed
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats
 reweave_edges:
 - Orbital data center governance gaps are activating faster than prior space sectors as astronomers challenged SpaceX's 1M satellite filing before the public comment period closed|supports|2026-04-11
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats|supports|2026-04-12
 ---
 
 # SpaceX's 1 million orbital data center satellite filing represents vertical integration at unprecedented scale creating captive Starship demand 200x larger than Starlink